[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-blood-flow\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-blood-flow":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,66,92,118,147,169,199,227,248],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":38,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100625406","long-term-effects-of-walnut-consumption-on-brain-function-100625406",false,"NCT07422220","Long-Term Effects of Walnut Consumption on Brain Function","Long-Term Effects of Walnut Consumption on Brain Function in Men and Women With Abdominal Obesity","WalBrain","Inclusion Criteria:\n\n* Men and women, aged between 45-75 years\n* Women postmenopausal: two or more years after last menstruation\n* Waist circumference of ≥102 cm for men and ≥88 cm for women (abdominal obesity)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Allergy or intolerance to walnuts\n* Left-handedness (effects on brain function differ between left- and right-handed adults)\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements (e.g., dietary fiber or antioxidant dietary supplements (vitamin C and E), fish or seaweed oil capsules) known to interfere with the main outcomes as judged by the principal investigators\n* Use of medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)",true,"ALL","45 Years","75 Years",{"count":22,"type":23},55,"ESTIMATED","INTERVENTIONAL",[26],"NA","Rationale: Healthy foods, including mixed nuts, may improve brain function, which is essential for cognitive and metabolic health, and may contribute to improved food intake regulation. It is therefore important to investigate the specific effects of walnuts on cerebral blood flow responses before and after intranasal insulin administration, as well as their associated functional benefits. The investigators hypothesize that long-term walnut consumption improves vascular function and insulin-sensitivity in the brain, thereby enhancing cognitive performance and appetite control in abdominally obese men and women. Objective: The primary objectives are to investigate in abdominally obese adults the effects of 24-week walnut consumption on (regional) vascular function and insulin-sensitivity in the brain, while the investigators will also assess changes in cognitive performance and appetite-related brain reward activity (secondary objectives). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL). Study design: This intervention study will have a randomized, controlled parallel design. The total study duration will be 24 weeks. Study population: Fifty-five abdominally obese men and (postmenopausal) women (aged 45-75 years) without a history of cardiovascular diseases or complaints will participate. This study population is expected to have a decreased cerebral blood flow at baseline and are also at increased risk of cognitive impairment, allowing for improvement by the intervention. Intervention: Study participants will receive daily 50 g (about 15% of energy) of raw walnuts (walnut intervention) or no walnuts (control intervention) for 24 weeks. Main study parameters\u002Fendpoints: At baseline and after 24 weeks (follow-up), participants will visit the research facilities for assessments. The primary endpoint is the difference in the cerebral blood flow response before and after intranasal insulin administration between the walnut and control intervention. Cognitive performance will be assessed, while the investigators will also focus on appetite-related brain reward activity (secondary outcomes).",[29,30,31,32,33,34,35,36,37],"Healthy","Brain Insulin Sensitivity","Cerebral Blood Flow","Brain Vascular Function","Satiety and Food Intake","Food Reward","Cognitive Performance","Abdominal Obesity","Cognitive Decline",[39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Walnuts","Juglans","Brain vascular function","Brain insulin sensitivity","Satiety","Food reward mechanisms","Cognitive performance","Abdominal obesity","Cognitive decline","pCASL MRI","fMRI","CANTAB","Intranasal insulin","Food cues","NOT_YET_RECRUITING","2026-02-18",{"date":56,"type":57},"2026-02-19","ACTUAL",{"date":59,"type":23},"2026-02",{"date":61,"type":23},"2027-08",{"name":63,"class":64},"Maastricht University Medical Center","OTHER",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":18,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":65},"100625800","cerebral-blood-flow-in-term-and-preterm-neonates-using-doppler-ultrasonography-100625800","NCT07427342","Cerebral Blood Flow in Term and Preterm Neonates Using Doppler Ultrasonography","Comparative Analysis of Cerebral Blood Flow in Term and Preterm Neonates Using Doppler Ultrasonography","Inclusion Criteria:\n\n* Term neonates ≥ 37 weeks of gestational age.\n* Preterm neonates \\\u003C 37 weeks' gestational age.\n* Hemodynamically stable infants at the time of examination.\n* Parental\u002Fguardian informed consent obtained.\n* Within the first 48 hours after birth.\n* Birth weight appreciate for gestational age.\n\nExclusion Criteria:\n\n* Infants aged more than 48 hours after birth.\n* Neonates with major congenital anomalies (cardiac, neurological, or craniofacial).\n* Suspected or confirmed intracranial hemorrhage or brain malformations, such as intraventricular hemorrhage, may influence RI measurements and interfere with accurate assessment of cerebral blood flow.\n* Neonates requiring inotropic support at the time of scan.\n* Neonates with severe respiratory instability or mechanical ventilation (unless included intentionally).\n* Infants with sepsis or metabolic derangements affecting cerebral perfusion.","1 Hour","48 Hours",{"count":76,"type":23},200,"OBSERVATIONAL","This study aims to evaluate cerebral blood flow in stable term and preterm newborns using Doppler ultrasonography. By measuring and comparing PSV, EDV, RI, and PI in the main brain arteries, the study seeks to identify normal physiological differences in cerebral perfusion across different gestational ages. The main goal is to establish reference values that can guide clinical monitoring, allow early detection of blood flow problems, and improve neuroprotective care in newborns.",[31],[31,81,82],"Doppler Ultrasonography","Term and Preterm Neonates","2026-02-17",{"date":85,"type":57},"2026-02-23",{"date":87,"type":23},"2026-04-15",{"date":89,"type":23},"2027-12-15",{"name":91,"class":64},"Assiut University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":17,"sex":18,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":65},"100609294","the-role-of-estrogen-and-testosterone-in-determining-brain-blood-flow-and-metabolic-regulation-in-humans-100609294","NCT07212712","The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans","Inclusion Criteria:\n\nThe investigators will recruit healthy young (18-40 years) males (n = 25) and females (n = 25). Females must be naturally cycling (i.e., no oral or hormonal contraceptives), not pregnant, and premenopausal. Participants must be normotensive (\\\u003C140\u002F90 mmHg \\& \\>90\u002F60 mmHg) and have no medical history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, and renal disease assessed by a study questionnaire. A recent physical examination (within 1 year of participation) from a family physician or a completed physical examination by the study doctor is required prior to participation. All subjects will sign an informed consent form prior to participation.\n\nParticipants will be excluded if they meet any of the following criteria:\n\n* Hypertensive (≥140\u002F90 mmHg) or hypotensive (≤90\u002F60 mmHg)\n* BMI ≥ 30 kg\u002Fm2\n* Fasting blood glucose ≥ 100 mg\u002FdL\n* Abnormal results on standard blood hematology tests (e.g., complete blood count, comprehensive metabolic panel)\n* Males with hypogonadism (total testosterone ≤ 262 ng\u002FdL, per Endocrine Society recommendations)\n* Any history of cerebrovascular, cardiopulmonary, cardiovascular, neuromuscular, or renal disease\n* Any liver dysfunction or disease\n* Taking any cardiovascular medications or medications that would interfere with study medications (e.g., strong organic anion transporting polypeptide 1B1 inhibitors)\n* Contraindications or sensitivities to study medications\n* Current eating disorder (defined as \\>2 on the 'SCOFF' questionnaire 67)\n* Current smokers\n* Females with an irregular menstrual cycle or any medical conditions affecting the menstrual cycle (normal cycle defined as 21-35 days from menstrual cycle diary)\n* Females who are pregnant (assessed with pregnancy test at screening and prior to starting medications), breastfeeding, or planning to conceive within 3 months\n* Females using hormonal birth control (Copper intrauterine devices \\[IUDs\\] will be allowed as they do not change systemic hormone levels)\n* Females who are peri- or postmenopausal (as determined by STRAW criteria 68)\n* History of hormone-sensitive cancers (i.e., breast, ovarian, uterine or prostate)\n* Z-score \\\u003C -2 as assessed with DXA scan (to determine risk of decrease in bone mineral density)\n* Assessed using the Center for Epidemiologic Studies Depression (CES-D) scale, participants with a score \\> 16 at screening unless otherwise approved by the study MD","18 Weeks","40 Weeks",{"count":101,"type":23},50,[26],"Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.",[31,105,106,107,108],"Cerebral Blood Flow Regulation","Sex Differences","Exercise","Vascular","2026-02-06",{"date":111,"type":57},"2026-02-10",{"date":113,"type":23},"2026-04-01",{"date":115,"type":23},"2027-12-31",{"name":117,"class":64},"University of British Columbia",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":24,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":65},"100568556","a-nutritional-intervention-for-body-brain-and-longevity-effects-nibble-100568556","NCT06682767","A Nutritional Intervention for Body, Brain, and Longevity Effects (NIBBLE)","A Nutritional Intervention for Body, Brain, and Longevity Effects (NIBBLE) - A Randomized Open-label Intervention of the Fasting-mimicking Diet (FMD)","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 45-65 years at screening\n4. Carrier of at least one copy of the APOE e4 allele\n5. BMI 20-39kg\u002Fm2 (inclusive) at screening\n6. On a stable medication regimen for at least 3 months.\n\nExclusion Criteria:\n\n* Has any medical disease or condition that, in the opinion of the principal investigator (PI) or appropriate study personnel, precludes study participation\\* (\\*Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial);\n* Significant depression (PHQ-9\\>9) or generalized anxiety (GAD-7\\>9)\n* Diagnosis of a significant neurological condition such as multiple sclerosis, epilepsy, Parkinson's disease, major stroke\n* Contraindications to MRI such as claustrophobia, cardiac pacemaker, etc.\n* Current adherence or adherence within the past 3 months to a specialized diet (e.g. ketogenic, paleo, intermittent fasting, raw food, vegan)\n* Food allergies (e.g. dairy, eggs, fish\u002Fshellfish, peanuts, tree nuts, soy, wheat, sesame, corn)\n* Diagnosis of mild cognitive impairment or dementia; use of an FDA-approved medication for Alzheimer's disease; MoCA\\\u003C23\n* Diabetes (hbA1c \\>6.5%) or anti-diabetic medications\n* History of gastric bypass;\n* Inflammatory bowel disease\n* Small or large bowel resection\n* Subjects with recent weight loss (\\>5%), use of weight loss medication, participated in a weight loss program in the past 3 months\n* Use of immune suppression drugs;\n* Contraindication for study foods (special food needs and allergy);\n* Women who are pregnant, lactating, or trying to conceive\n* Alcohol dependency (alcohol intake greater than two drinks per day for women and three drinks per day for men)\n* Current smoker or tobacco use within 3 months.\n* Active malignant cancer or history of malignancy within the last 1 yea1s (except non-melanoma skin cancer)\n* Serious psychiatric disorders such as schizophrenia, bipolar disorder, eating disorders\n* Persons with allergy to animal dander or animal-instigated asthma","65 Years",{"count":127,"type":23},40,[26],"The study aims to evaluate the safety, feasibility, and preliminary efficacy of six-month fasting-mimicking (FMD) relative to Dietary Guidance intervention in middle-aged adults at elevated risk for Alzheimer's disease due to the apolipoprotein (APOE) ε4 allele. Participants randomly assigned to the FMD intervention will consume a FMD for 5-days each month over a period of 6-months.",[31,131],"APOE 4",[131,133,134,135,136,137],"prevention","nutritition","fasting mimicking diet","diet","Alzheimer's disease","2026-02-04",{"date":140,"type":57},"2026-02-09",{"date":142,"type":23},"2026-03",{"date":144,"type":23},"2027-03",{"name":146,"class":64},"Cedars-Sinai Medical Center",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":17,"sex":18,"minAge":154,"maxAge":20,"enrollmentInfo":155,"targetDuration":4,"studyType":24,"phases":156,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":65},"100620260","high-dairy-food-patterns-and-gut-brain-axis-100620260","NCT07355309","High-Dairy Food Patterns and Gut-Brain Axis","Longer-term Effects of High-dairy Food Patterns on the Gut-brain Axis in Adults With Overweight or Obesity","Inclusion Criteria:\n\n* Men and postmenopausal women (≥ 2 years since last menstruation);\n* Aged between 40-75 years;\n* BMI between 25-35 kg\u002Fm2 (overweight or obese);\n* Low-to-moderate habitual dairy consumption (≤ 3 servings\u002Fday);\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL;\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL;\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL;\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg;\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months).\n\nExclusion Criteria:\n\n* Left-handedness;\n* Milk protein allergy or lactose intolerance;\n* Current smoker, or smoking cessation \\\u003C 12 months;\n* Familial hypercholesterolemia;\n* Abuse of drugs;\n* Alcoholic intake \\>3 standard drinks\u002Fday;\n* Use of medications, food products or dietary supplements affecting glucose, lipid, or blood pressure regulation, gut microbiota or mental or neurological function, judged by the principal investigator;\n* Use of antibiotics within the previous month;\n* Use of other biomedical investigational products within the previous month;\n* Participation in another clinical trial within the past month;\n* Severe medical conditions including type 2 diabetes, epilepsy, asthma, kidney failure, COPD, inflammatory bowel disease, autoimmune diseases, or rheumatoid arthritis;\n* History of cardiovascular events (e.g., heart attack, stroke) or active cardiovascular disease;\n* Contra-indications for MRI imaging (e.g. pacemaker, metal implants, claustrophobia);\n* Willing to donate blood starting from 8 weeks before the study begins, throughout the study, and for 4 weeks after its inclusion;\n* Difficult to venipuncture as evidenced during the screening visit.","40 Years",{"count":127,"type":23},[26],"Disturbances in brain insulin sensitivity are associated not only with obesity and type 2 diabetes, but also with brain aging and cognitive decline. Longitudinal studies suggest that dietary patterns, particularly those high in dairy intake, may impact brain function via the gut-brain axis. Indeed, dairy foods are known to modulate gut microbiota and may, through this pathway, not only improve brain insulin sensitivity and cognitive performance, but also mental health and appetite regulation. However, underlying mechanisms remain largely unexplored. The primary objective of this study is to evaluate, in older adults with overweight or obesity, the effects of a high-dairy food pattern (4-5 daily servings of (butter)milk, cheese, yogurt, or cottage cheese) compared to a low-dairy food pattern (≤1 serving daily) on (regional) brain vascular function and insulin sensitivity. These outcomes will be quantified using the non-invasive MRI perfusion technique Arterial Spin Labeling (ASL), which assesses cerebral blood flow (CBF) in response to intranasal insulin, a validated physiological marker of brain insulin sensitivity. Secondary objectives include changes in cognitive performance (via the CANTAB neuropsychological test battery), gut microbiota composition (via shotgun metagenomic analysis of fecal samples), and appetite-related brain reward activity (via BOLD-fMRI with food cues). Exploratory analyses include conventional cardiometabolic risk markers (blood pressure, lipid and glucose metabolism), and perceivable (consumer) benefits.",[30,32,31,35,159,160],"Appetite Control","Gut Microbiota","2026-01-12",{"date":163,"type":57},"2026-01-21",{"date":165,"type":23},"2025-12-22",{"date":167,"type":23},"2027-04-01",{"name":63,"class":64},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":17,"sex":18,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":65},"100599283","external-carotid-blood-flow-in-individuals-with-post-bariatric-hypoglycemia-100599283","NCT07082478","External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia","External Carotid Blood Flow Dynamics in Individuals With Post-Bariatric Hypoglycemia (PBH): Pilot Study","Inclusion Criteria:\n\n* Age 18-70 years of age, inclusive at screening.\n* Individuals able to provide informed consent and follow all study procedures, including complete daily food, activity, and symptom diaries, and willingness to provide access to medical record review.\n* For healthy control group: individuals without a history of upper gastrointestinal surgery and without reported symptoms of hypoglycemia.\n* Individuals with access to personal iPhone running operating system 16 (iOS) or later versions (not feasible for Android platform users) and a password-protected home Wi-Fi network.\n\nExclusion Criteria:\n\n* History of coronary artery disease or presence of 2 or more risk factors including diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, and active tobacco use.\n* History of myocardial infarction, unstable angina or revascularization within the past 6 months.\n* History of syncope (unrelated to hypoglycemia) or diagnosed cardiac arrhythmia.\n* Documented hypoglycemia occurring in the fasting state (\\> 12 hours fast).\n* Concurrent administration of β-blocker therapy.\n* Vigorous physical activity within 24 hours prior to assessment.\n* Seizure disorder (other than with suspect or documented hypoglycemia).\n* Hematocrit \\\u003C 33% (women) or \\\u003C36% (men) within the past 6 months.\n* History of insulinoma.\n* Use of central nervous system-active medications, including: antidepressants, anxiolytics, antipsychotics, stimulants, antiepileptics, sedatives and opioids.\n* History of severe neurologic vascular disease (e.g. cerebrovascular disease\u002Fstroke).\n* History of previous diseases associated with dysautonomia (e.g. multiple system atrophy, multiple sclerosis, Parkinson's disease).\n* Impaired hepatic function (aspartate amino transaminase and\u002For alanine amino transaminase \\>2x upper limit of normal range), as determined within the past 6 months.\n* Impaired renal function (serum creatinine \\>1.5 mg\u002FdL), as determined within the past 6 months.\n* Serious psychiatric or substance abuse disorders (e.g. alcohol, opioid, cocaine use disorder), as judged by the study investigator.\n* Non-consent or inability to comply with study procedures.\n* Current pregnancy and\u002F or lactation.\n* Vulnerable individuals (e.g., fetuses, children, prisoners) and those judged by the investigator to be unsuitable for the study.\n* Individuals wearing earrings or other jewelry in the left ear who are unable or unwilling to remove them for the duration of the study.\n* Unwillingness to wear study masked CGM for duration of study","18 Years","70 Years",{"count":179,"type":23},5,"This is a pilot study (small-scale study) that aims to understand more about how blood flow changes in people who have low blood sugar after bariatric surgery (post-bariatric hypoglycemia) compared to those who have had surgery without hypoglycemia, those who have hypoglycemia without surgery, or those who do not experience low blood sugar.\n\nThis study has two phases. This is the first phase, and the purpose is to test comfort and feasibility of a novel in-ear wearable device (Lumia Health) that measures blood flow changes to the head. Information from the study will help the investigators determine if the device is suitable to be used in the second phase of the study.",[182,31],"Hypoglycemia",[184,185,186,187,188],"hypoglycemia","postprandial hypoglycemia","bariatric surgery","autonomic dysfunction","cerebral blood flow","RECRUITING","2025-11-26",{"date":192,"type":57},"2025-11-28",{"date":194,"type":57},"2025-07-28",{"date":196,"type":23},"2026-09-15",{"name":198,"class":64},"Joslin Diabetes Center",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":17,"sex":18,"minAge":206,"maxAge":20,"enrollmentInfo":207,"targetDuration":4,"studyType":24,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":65},"100606609","effects-of-wild-blueberry-consumption-on-brain-function-in-elderly-100606609","NCT07177781","Effects of Wild Blueberry Consumption on Brain Function in Elderly","Longer-term Effects of Wild Blueberry Consumption on Brain Function in Older Men and Women","Inclusion Criteria:\n\n* Men and women, aged between 60-75 years\n* BMI between 25-35 kg\u002Fm2 (overweight or obese)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study.\n* No difficult venipuncture as evidences during the screening visit.\n\nExclusion Criteria:\n\n* Allergy or intolerance to berries\n* Left-handedness\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators\n* Use medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis.\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident.\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)","60 Years",{"count":208,"type":23},36,[26],"Impaired brain vascular function precedes the development of reduced cognitive performance, while brain insulin-resistance is associated with cognitive decline. Evidence from epidemiological studies has already suggested beneficial effects of wild blueberry consumption on cognitive performance. However, underlying mechanisms have not yet been established, while well-controlled trials on longer-term effects of wild blueberries on cognitive performance are highly needed. This study hypothesizes that longer-term wild blueberry intake improves (regional) brain vascular function and insulin-sensitivity, thereby improving cognitive performance in older men and women. The primary objectives are to investigate in older adults the effect wild blueberry consumption on (regional) vascular function and insulin-sensitivity in the brain, and to focus on changes in cognitive performance as assessed with the CANTAB neuropsychological test battery (i.e., secondary objective). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be non-invasively quantified by the non-invasive gold standard magnetic resonance imaging (MRI)- perfusion method Arterial Spin Labeling (ASL).",[212,32,31],"Brain Insulin-sensitivity",[45,214,41,215,216,217,218],"Brain insulin-resistance","Cerebral blood flow","Wild blueberry","Brain insulin-sensitivity","Anthocyanin","2025-09-10",{"date":221,"type":57},"2025-09-17",{"date":223,"type":57},"2024-12-05",{"date":225,"type":23},"2026-08-31",{"name":63,"class":64},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":17,"sex":18,"minAge":206,"maxAge":20,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":65},"100597342","effects-of-protein-supplementation-on-brain-function-100597342","NCT07057245","Effects of Protein Supplementation on Brain Function","Effects of Daily Protein Supplementation on Brain Function in Older Adults With Overweight or Obesity","Inclusion Criteria:\n\n* Men and women, aged between 60-75 years (older adults)\n* BMI between 25-35 kg\u002Fm2 (overweight or obese)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Intolerant to milk products or fava bean allergy\n* Vegetarians\n* Left-handedness\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators\n* Use medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)",{"count":235,"type":23},25,[26],"Protein-rich foods may improve brain insulin-sensitivity, which is important for cognitive and metabolic health, and may also translate into an improved food intake regulation. It is therefore pertinent to delineate the effects of plant-derived proteins, which are a more sustainable alternative to animal-derived proteins, on brain insulin-sensitivity and related functional benefits. The hypothesis is that daily plant-derived or animal-derived protein supplementation improves brain vascular function and insulin-sensitivity, thereby improving cognitive performance and appetite control in overweight or obese older men and women.\n\nThe primary objective is to investigate in overweight or obese older adults the effect of daily protein supplementation for two weeks with either a plant-derived protein or an animal-derived protein on vascular function and insulin-sensitivity in the brain, while changes in cognitive performance and appetite-related brain reward activity will also be evaluated (secondary study objectives). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be quantified by the gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL).",[32,239,43,31,30],"Cognitive Function","2025-06-30",{"date":242,"type":57},"2025-07-09",{"date":244,"type":23},"2025-07-02",{"date":246,"type":23},"2025-12-31",{"name":63,"class":64},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":17,"sex":18,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":24,"phases":259,"briefSummary":260,"conditions":261,"keywords":265,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":65},"100581830","hypertension-and-cerebrovascular-hemodynamics-in-general-anaesthesia-100581830","NCT06855407","Hypertension and Cerebrovascular Hemodynamics in General Anaesthesia","The Effects of Induced Hypertension on Cerebrovascular Hemodynamics During General Anaesthesia","Inclusion Criteria:\n\n* ASA classification 1-3\n* BMI 18,5-29.9\n* MMSE \\> 23\n* Elective surgery planned.\n\nExclusion Criteria:\n\n\\- Pacemaker or other contraindications for MRI.","50 Years","80 Years",{"count":258,"type":23},30,[26],"During anesthesia, blood pressure-raising medications are often required to achieve an adequate blood pressure level. However, there is limited knowledge about what constitutes an adequate blood pressure to ensure sufficient blood flow to the brain. This project aims to map the relationship between blood pressure and brain blood flow using an MRI scanner. The results will contribute to a better understanding of this relationship and lead to improved management of brain blood flow during surgery on anesthetized patients.\n\nHow does the project work?\n\nDay 1 Before planned surgery, participants will meet with an anesthesiologist for information and assessment. An MRI scan of the brain will be conducted while participants are awake. The MRI examination has no side effects or risks. The space inside the MRI scanner is tight, especially around the head. If discomfort is experienced, the examination will be stopped immediately. The machine is noisy, so hearing protection will be provided, and communication with staff will be possible throughout the examination. The scan takes approximately 30 minutes, during which participants only need to lie still and relax.\n\nDay 2 After planned surgery, an anesthesiologist and an anesthesia nurse will transfer participants to the MRI scanner while still under anesthesia. Participants will not be woken up between surgery and the MRI scan; instead, transportation will occur while still anesthetized, following standard hospital procedures.\n\nParticipants will remain under the same anesthetic drugs as during the surgery. The same blood pressure-raising medication, norepinephrine, will be continuously used.\n\nNo additional drugs, beyond those necessary for normal anesthesia, will be administered before the MRI examination.\n\nThe entire project will take about 1.5 hours in addition to the surgery. If an arterial catheter (a blood pressure monitor via an artery in the wrist) is not already in place, one will be inserted while participants are asleep.\n\nBefore the MRI examination:\n\nBaseline examination - If any abnormalities are detected, the scan will be stopped, and follow-up by a doctor will occur.\n\nBlood pressure increase - Blood pressure will be raised by approximately 30% (equivalent to mild physical activity, such as jogging).\n\nFollow-up scan at the higher blood pressure level. Blood pressure returns to normal. All blood pressure levels will remain within clinically acceptable ranges for anesthetized patients and will be regulated with the same medication as used during the surgery.\n\nAfter the MRI:\n\nParticipants will be woken up in the anesthesia preparation room next to the MRI scanner.\n\nThe arterial catheter will be removed before awakening. Participants will be transported to the postoperative unit for monitoring. The surgeon responsible for care will determine the discharge time.\n\nPossible Risks and Side Effects of Participation\n\nTransporting an anesthetized patient for an MRI scan outside the operating room carries some risks. However, the hospital has established procedures for daily transportation of anesthetized patients and a structured division of responsibilities to manage unexpected situations. Monitoring will be conducted by an experienced anesthesiologist and anesthesia nurse throughout the procedure.\n\nRoutine monitoring includes blood pressure, heart rate, depth of anesthesia, and oxygen levels.\n\nNo long-term effects have been observed from MRI scans or short-term anesthesia for these examinations.\n\nMost complications related to general anesthesia occur during induction or awakening, and these risks exist regardless of study participation.\n\nStudy participation may slightly increase the risk of IV lines or breathing tubes becoming dislodged due to movement while anesthetized.\n\nA prolonged period under anesthesia may cause slight additional fatigue upon waking.\n\nTo ensure understanding of the information about this study, participants will take a simple cognitive test (5 minutes) before surgery.\n\nIf any unexpected complications arise during surgery, study participation will be discontinued. If the MRI scan reveals any abnormalities, referral to a neurologist or neurosurgeon for further evaluation will be provided.\n\nWhat Happens to Collected Data?\n\nThe project will collect health information from medical records and MRI scans. All data will be pseudonymized (coded) so that it cannot be linked to individual participants.\n\nThe key to decoding this information will be stored securely by the research nurse at the Neuro-Head-Neck Center (NHHC).\n\nOnly authorized research personnel will have access to the pseudonymized data. Information will be protected in accordance with the General Data Protection Regulation (GDPR).",[262,31,263,264],"Anesthesia","Regional Cerebral Oxygen Saturation","Blood Pressure",[266],"induced hypertension","2025-03-10",{"date":269,"type":57},"2025-03-13",{"date":271,"type":57},"2024-12-06",{"date":273,"type":23},"2027-06-01",{"name":275,"class":64},"Umeå University"]